Common diabetes drug appears to lower breast cancer risk

Share this article:

Metformin, usually prescribed to help control blood glucose levels in persons with type 2 diabetes, may play a role in the prevention or management of breast cancer: The widely used oral drug has been linked with lower incidence of invasive breast cancer among participants in the Women's Health Initiative (WHI) clinical trials.

Rowan T. Chlebowski, MD, PhD, of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Los Angeles, California, and colleagues explained in Journal of Clinical Oncology that although emerging evidence suggests metformin may reduce breast cancer incidence, reports are mixed and few provide information on tumor characteristics. To assess the associations among diabetes, metformin use, and breast cancer, the researchers studied WHI study participants.

Of the 68,019 postmenopausal women followed, 3,401 had diabetes at study entry. Over a mean of 11.8 years, 3,273 invasive breast cancers were diagnosed. Women with diabetes using medications other than metformin had a slightly higher incidence of breast cancer compared to women without diabetes, but women with diabetes who were metformin users were less likely to have breast cancer. The association was seen for cancers positive for both estrogen receptor (ER-positive) and progesterone receptor (PR-positive), and for those that were negative for human epidermal growth factor receptor 2 (HER2-negative).

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Y-90 radioembolization: A new treatment for hepatic metastases from breast cancer

Yttrium-90 radioembolization is a minimally invasive treatment that may slow disease progression in breast cancer that has metastasized to the liver.

More sensitive testing may better define prognosis and treatment for leukemia

Nearly half of patients with the most common form of adult leukemia may have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.

Doxorubicin-ifosfamide combo improves progression-free survival in soft-tissue sarcoma

A new European study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma.